Kornimate/medical-research-clean huggingface dataset:
the effect of eggs and egg products on macular pigment

Conditions: Age-related Macular Degeneration

Summary: age-related macula degeneration (amd, encompassing both dry and wet form), the late stage of age-related maculopathy (arm), is the leading cause of blindness in many developed countries in older persons (usually over 60 years of age). visual compromise rises exponentially after the age of 70 with a 5-year incidence of around 1%. studies have shown a possible protective effect of lutein on progression of amd, where visual acuity improves after increased lutein intake. the incidence of bilateral amd in persons with unilateral late arm observed over a period of 10 years is over 50% with a 2.1-2.8% overall incidence in the study population. blue light hazard (excitation peak 440 nm) was shown to have a major impact on photoreceptor and rpe function inducing photochemical damage and cellular apoptosis, leading to retinal degeneration in an animal study. the current belief is that lutein accumulated in the macular region helps in the prevention of blindness by absorbing blue light and protecting the retina from oxidative stress. with the lipid matrix of the egg yolk being a proven vehicle for the efficient absorption of dietary lutein, it might be possible to increase plasma levels of lutein to therapeutic levels and control or prevent amd. this, the investigators hope, will be accomplished by means of filtering out harmful blue light and the scavenging of free radicals by lutein and zeaxanthin.

this will be a randomized placebo-controlled trial. the total study time will be two years of which 3 months are actual trial and follow-up time. every individual will have 3 measuring points at set intervals. at every measuring point (days 1, 45 and 90), these subjects will undergo 6 different non-invasive measuring techniques. these are the mean visual acuity test using the early treatment diabetic retinopathy study (etdrs) chart, contrast sensitivity using the pelli-robson chart, scanning laser ophthalmoscope (slo), optical coherence tomography (oct) and heterochromatic flicker photometry (hfp) and the reflectometer. a questionnaire will be taken at the beginning of the trail. the invasive part of the study involves blood sampling at all three times, measuring the serum concentration of lutein, zeaxanthin, omega-3 and lipoprotein using the hplc analysis.

Eligibility criteria:
inclusion criteria: * no history of arm or amd * 18 years and older * non-smoker * no ocular media opacity * uses no nutritional supplements containing lutein, zeaxanthin or omega-3 * bmi \< 30 * no known cardiovascular disease exclusion criteria: * diabetes * other known eye disease * known lipid metabolism disease * blood lipid level modifiers (e.g., statin) * known allergy to eggs or egg products

Keywords: macular pigment amd arm
multimodal imaging for surveillance in patients with oral potentially malignant disorders

Conditions: Dysplasia; Lip and Oral Cavity Carcinoma; Oral Disorder; Premalignant Lesion

Summary: this early phase i trial studies how well multimodal imaging works for surveillance in patients with oral potentially malignant disorders. new types of imaging devices may help doctors decide if a lesion in the mouth is pre-cancerous or cancerous.

primary objectives: i. to compare standard white light examination to multimodal imaging for detection of high grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially malignant disorders (opmd). secondary objectives: i. to determine qualitative and quantitative diagnostic assessment of patients who agree to undergo imaging and have images of sufficient quality. ii. to compare expression of molecular biomarkers to results from white light examination, multimodal imaging and pathologic assessment in a subset of patients who have invasive biopsies or resection. iii. to compare cytologic results from brush biopsy specimens to white light examination and multimodal imaging results. outline: participants undergo ps2.1/ps3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. patients also undergo brush biopsy and incisional biopsy. procedures are repeated every 3-4 months for 2 years. after completion of study treatment, patients are followed up at 30 days.

Eligibility criteria:
inclusion criteria: * subjects who are willing to participate. * adult subjects with: a. clinically evident oral premalignant lesion (opl) or suspicious oral mucosal lesion. or b. pathologic diagnosis of dysplasia or c. history of resected oral cancer or d. oral potentially malignant disorder (opmd) or e. history of tobacco and/or alcohol exposure. * ability to understand and willingness to sign a written informed consent document (icd). exclusion criteria: * known allergy to proflavine or acriflavine. * pregnant females.
the effects of hesperidin and flaxseed on biochemical factors and hepatic fibrosis in nonalcoholic fatty liver disease

Conditions: Non Alcoholic Steatohepatitis

Summary: to study the effects of hesperidin and flaxseed supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with nonalcoholic steatohepatitis (nash), 50 patients who referred to gastrointestinal (gi) clinic with steatosis grade 2 and 3 will be randomly allocated to contol group or 2 capsules hesperidin and 30 gram flaxseed for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. at the first and the end of the intervention, lipid profiles, liver enzymes, some inflammatory markers, and liver fibrosis will be assessed and compared between groups.


Eligibility criteria:
inclusion criteria: - age of 18 to 70 years * body mass index (bmi) between 25-40 * sonographic findings compatible with hepatic steatosis (degree 2 or more) exclusion criteria: * diabetes * taking any kind of antibiotics two weeks before recruitment * history of alcohol consumption * pregnancy or lactation * professional athletes * other liver disease (viral/etc) * use of drugs such as calcium channel blockers, high dose synthetic estrogens, methotrexate , amiodarone, steroids, chloroquine, immunosuppressive drugs, lipid-lowering agents, metformin and vitamin e * a history of hypertension, cardiovascular disease, pulmonary disease, renal disease \& celiac disease; cirrhosis * history of upper gi surgery / prior surgical procedures such as jejunoileal or jejunocolic bypass, gastroplasty * following program to lose weight in recent 3 mo * a history of hypothyroidism or cushing's syndrome
nerve changes in patients who are undergoing chemotherapy or biological therapy for cancer

Conditions: Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: learning about the effects of chemotherapy and biological therapy on nerve function may help doctors plan treatment and help patients live more comfortably. purpose: this clinical trial is studying peripheral neuropathy in patients who are receiving chemotherapy or biological therapy for cancer.

objectives: * determine the change in peripheral nerve function in cancer patients during and after treatment with chemotherapy or biologic therapy. * determine the clinical measurement of hearing-related air and bone conduction and vibratory sensation in these patients. * correlate the changes in orthostatic blood pressure using both the vasotrac automated blood pressure device and the standard clinical automated blood pressure equipment. * determine the patient's perception of hearing quality before and after treatment with chemotherapy or biologic therapy. outline: this is a multicenter study. patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy. projected accrual: a total of 20 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed diagnosis of cancer * scheduled to be treated with 1 of the following agents: * cisplatin/paclitaxel combination * biologic therapy with high-dose interferon alfa patient characteristics: * normal vision or vision corrected with glasses or contact lenses * no diseases or disorders reducing peripheral nerve function, including any of the following: * diabetes mellitus * hiv/aids * uremia * spinal injuries * alcoholism * cns problems * no hearing impairment prior concurrent therapy: * no prior biologic therapy or neurotoxic chemotherapy

Keywords: neurotoxicity unspecified adult solid tumor, protocol specific
palliative care interventions for outpatients newly diagnosed with lung cancer: phase ii

Conditions: Lung Cancer

Summary: the focus of the study is to test a nurse-led telephone-based palliative care intervention on improving the delivery of care for patients with newly diagnosed lung cancer. the study is a three site randomized control trial to determine the efficacy of the intervention on improving patients' quality of life, symptom burden, and satisfaction of care. additionally, the study will test an innovative care delivery model to improve patients' access to palliative care. the investigators will also determine the effect of the intervention on patient activation to discuss treatment preferences with their clinician and on clinician knowledge of patients' goals of care.

patients meeting entry criteria will be randomized to the intervention arm, palliative care plus usual care, or the usual care arm. patients randomized to the intervention arm will receive usual oncologic care and phone calls from a nurse. outcome measures will be collected at baseline and at the end of the patients' primary cancer treatment. the study will be performed at the puget sound health care system, birmingham va and portland va. the investigators will recruit individuals (n=138) with lung cancer over 2.5 years. the primary objective is to determine the efficacy of the nurse-led telephone-based palliative intervention on improving patients' quality of life, symptom burden, and satisfaction of care. in addition, using validated instruments, the investigators will assess the effect of the intervention on patient activation to discuss treatment preferences with their clinician and on clinician knowledge of patients' goals of care. the results of this study will inform a future effectiveness/implementation study.

Eligibility criteria:
inclusion criteria: patients diagnosed at the puget sound health care system, birmingham va, or portland va with a primary diagnosis of lung cancer that requires more than surgical resection: * diagnosed within 8 weeks of recruitment * must have telephone access * ability to understand english * able to participate in informed consent process exclusion criteria: patients not eligible to participate in the study include those who are inpatients prior to randomization, * those who are under the care of palliative care or hospice at the time of randomization * those who have severe mental health disorders * those who are unable to speak directly with the nurse over the telephone * or those that have the inability to provide informed consent

Keywords: palliative care supportive care
care pathways for benchmarking on fragile hip fractures rapid recovery

Conditions: Quality Improvement; Hip Fractures

Summary: the aim of this project is to build an international community of centers of excellence in the care for fragile hip fracture rapid recovery patients. these centers of excellence will benchmark and share their expertise and experiences based on clinical and managerial data. in project is designed in five different phase: phase 1: literature review: identifying relevant key interventions and indicators phase 2: expert panel: expert panel for teams, management and policy makers phase 3: data collection: collection managerial data through retrospective patient record analysis on clinical indicators phase 4: statistical data analysis: data input, validation and statistical analysis phase 5: feedback and knowledge sharing: feedback report with anonymous benchmarking and knowledge sharing of the results.


Eligibility criteria:
inclusion criteria: * trauma related non-elective admission for hip fracture; * minimum age of 65 years; * the following hip fractures are included: femoral neck, femoral head, trochanteric and subtrochanteric fractures; * discharged or deceased before may 30th of 2019 exclusion criteria: * hip fracture is not the main reason for admission to emergency room; * additional ipsilateral fractures; * hip fracture resulting from in-hospital fall that occurred in the hospital where the patient receives hip fracture care.
investigating the effect of interval walking and qigong on people with knee osteoarthritis: pilot study

Conditions: Osteoarthritis, Knee

Summary: knee osteoarthritis (koa) causes pain and limited function that leads to a sedentary lifestyle. the sedentary lifestyle increases the risk of cardiovascular diseases. in addition, many subjects with koa have knee pain and sleep disturbance that limit their function, quality of life and cause body fatigue. walking exercise can benefit people with koa. however, continues walking for more than 30 minutes can increase pain that may stop people from participation in walking exercise. interval walking may complete the same amount of walking exercise in several separate time periods, without causing extra pain in people with koa. mind-body exercise may improve sleep and pain in people with koa. this study will help researchers to find out whether the interval walking, or mind-body exercise may help people with koa to improve their pain, fitness level, sleep quality, exercise participation, fatigue, and quality of life. by doing this study, researchers hope to learn more about the interval walking or mind-body exercise in people with koa.


Eligibility criteria:
inclusion criteria are the following: 1. 60-79 years of age and diagnosed with koa by a physician or meet the acr criteria (95% sensitivity, and 69% specificity) for koa. the acr criteria include experiencing almost daily knee pain and having at least 3 of these 6 criteria: (1) age more than 50 years old, (2) less than 30 minutes of morning stiffness, (3) increased warmth of the knee, (4) crepitus with flexion or extension, (5) joints' bony enlargement , and (6) tenderness of joint line with palpation, or subject must be diagnosed radiologically, with grade ii or more according to the kellgren and lawrence rating scale. 2. frequent knee pain or aching on most of the preceding 30 days. 3. an average of mild to moderate pain intensity level (5 to 75 mm on the 100 mm vas) in the last 7 days 4. sedentary lifestyle assessed using 2011 compendium of physical activities questionnaire. the subject is considered sedentary if engaging in exercise or physical activity with metabolic equivalents of task (met) less than 4, not more than two times/week. exclusion criteria: 1. unwilling to attend 3 sessions/week at kirmayer fitness center 2. having other types of arthritis such as rheumatoid arthritis or gout 3. neurological disorders 4. cvd including hypertension that prevent them from engaging in walking exercise 5. currently using beta blocker medication 6. underwent any lower limb surgery during the past 6 months 7. a history of two or more incidents of fall during the last 6 months 8. current hip or spine pain that prevents them from engaging in walking exercise.
a pilot trial of an individualized web-based condom use intervention

Conditions: HIV

Summary: the purpose of this study is to evaluate the efficacy of an online intervention in increasing condom use among hiv+ gay males.


Eligibility criteria:
inclusion criteria: 1. are hiv-seropositive, 2. men who are having sex with men, 3. engaging in unprotected anal intercourse with a partner who is serostatus negative or unknown 4. age 18 years and older, 5. ability to read english 6. have access to a computer and internet. exclusion criteria: -

Keywords: condom use hiv+ gay males intervention tailored on-line internet web-based
early recovery after gastric cancer surgery

Conditions: Fasting; Malignant Neoplasm of Stomach

Summary: study preparation * to progress this prospective study, the investigators analyzed the retrospective data of 426 patients who had been managed with conventional critical pathway after gastric cancer surgery during last 1 year. * through this retrospective analysis, we decided the inclusion criteria which showed significantly the lower complication rate and shorter hospital stay. method for prospective study * patients who enroll in this prospective study are administered and are supplied a liquid diet one day before surgery without bowel preparation. * after gastric cancer surgery, they start sips of water on postoperative first day, and they are discharged once they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.

enrollment of patients * before the patients are enrolled in this study, they give us informed consents. * a liquid diet is supplied beginning from the morning of the day prior to operation to the midnight. operation and postoperative management * all procedures are approached by laparoscopic surgery, and partial gastrectomy with lymph node dissection are performed. * the patients who are considered to be difficult to progress early oral feeding in surgical field are excluded from the study. * nasogastric tube is not applied to patients. * postoperative pain is managed by non-opioid pain killer. * the patients are started on sips of water on the first postoperative day. * if they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. * we have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination. evaluation of patients - the patients are followed up to 30 days after discharge from hospital, and we check whether they are tolerable without any compliant and are readmitted.

Eligibility criteria:
inclusion criteria: * patients who are diagnosed with gastric adenocarcinoma * 65 years old and blew * patients are expected to be undergone distal subtotal gastrectomy * no complication by gastric cancer * no synchronous metastatic lesions * laparoscopic or robotic surgery * informed consent exclusion criteria: * previous gastrectomy history * combined surgery due to synchronous malignancy * patients with major organ dysfunction

Keywords: gastric cancer surgery early oral feeding fast track surgery
effect of a probiotic on grass pollen allergic rhinitis subjects

Conditions: Allergic Rhinitis

Summary: various studies in animals and humans have shown a potential beneficial effect of probiotics consumption on allergy. however, few studies exist that document their efficacy for upper airways allergies such as allergic rhinitis. the objective of this study is to investigate the effect of short-term oral administration of a lactobacillus paracasei on a nasal provocation test (npt) with grass pollen, performed out of pollen season. adult volunteers with allergic rhinitis are enrolled in a randomized, double-blind, placebo-controlled study, based on two 4-weeks cross-over periods of product consumption (probiotic-fermented milk versus placebo), separated by a washout period of 6-8 weeks. objective and subjective clinical parameters of npt as well as systemic and nasal immunological parameters are compared between the two treatment periods.


Eligibility criteria:
inclusion criteria: * age 18 to 35 years * history of allergic rhinitis to grass pollen confirmed by either a positive skin prick test (wheal diameter \>3 mm) or specific ige for grass pollen (\>0.35 ku/l) as titrated by unicap 100 (pharmacia diagnostics, uppsala, sweden) and no history of perennial rhinitis * a nasal reaction threshold of 10'000 standardized quality units (sqs)/ml grass pollen or less at the screening phase exclusion criteria: * any medical condition that could influence the study (pregnancy, viral or bacterial airway infection, active allergic rhinitis) * uncontrolled asthma (peak expiratory flow \<20% of volunteer's best personal value) * treatment with antihistamine or antibiotic treatment less than two weeks before enrolment or during the trial
safety and efficacy of mitomycin c-based hipec after srhcc and pm of hcc

Conditions: Hepatocellular Carcinoma; Peritoneal Metastasis; Hyperthymic; HCC

Summary: hepatocellular carcinoma (hcc) is featured by the spontaneously rupture when suffering severe cirrhosis and intratumoral overpressure. it is a fatal complication with an acute mortality. importantly, it is served as an independent risk factor for peritoneal metastasis (pm) of hcc with poor prognosis. the systematic agents effective to extrahepatic lesions confers modest efficacy towards pm. hipec, as a novel strategy, has been proved by overwhelming studies that it is effective to peritoneal malignant tumors. however, there is absence of prospective study of hipec efficacy towards hcc.


Eligibility criteria:
inclusion criteria: 1. hcc patients have been diagnosed by nccn clinical practice guidelines in oncology, hepatobiliary cancers, version 2.2021. 2. ecog score of 0-2 points; 3. child-pugh class a-b liver function only; 4. consistent with the diagnosis of srhcc: symptoms: acute abdominal pain and peritonitis; blood routine tests: decrease of erythrocyte count; increase of leucocyte count, especially the proportion of neutrophils; radiological features: contrast materials extravasation from lesions confirmed by abdominal contrast enhanced computed tomography or promethean magnetic resonance imaging; intraoperative findings of tumor rupture and postoperative pathology are more confidently conclusive. 5. consistent with pm of hcc: histological evaluations: biopsy of peritoneal nodules or ascites cytology or postoperative pathological verification; radiological diagnose: early enhancement and late wash-out radiological property of peritoneal nodule or mutual confirmation by two senior radiologists. 6. all of selections have received open or laparoscopic hepatectomy to reach complete macroscopic resection or less than 2.5mm of residual tumor tissue, which is equal to 0 or 1 degree of completeness of cytoreduction. 7. patients voluntarily participated and signed the informed consent. exclusion criteria: 1. contraindications of hipec, such as: extensive intra-abdominal adhesions caused by various reasons; complete intestinal obstruction; severe kidney insufficiency; myelosuppression caused by previous targeted therapy or own blood system disease; severe cardiovascular system disease; infection, especially abdominal infection; bleeding tendency or coagulation dysfunction; the vital signs are unstable; cachexia; 2. extraperitoneal metastasis; 3. patients who refuse to accept clinical trials; 4. those who are deemed unsuitable for inclusion by the researchers.